{
  "slug": "oncologists-say-prior-authorization-not-guidelines-delays-new-first-line-cancer-regimens",
  "url": "https://reports.brox.ai/insights/oncologists-say-prior-authorization-not-guidelines-delays-new-first-line-cancer-regimens",
  "title": "Prior authorization, not the evidence, is what delays 14 of 18 US oncologists from prescribing a new first-line cancer regimen",
  "question": "What makes an oncologist adopt a newly approved first-line cancer therapy straight away, rather than wait for guidelines, payer coverage or peers?",
  "answer": "14 of 18 US oncologists in the Brox HCP panel say prior authorization or coverage denials, not the trial data or the guideline listing, are what most often delay their first prescription of a newly approved first-line cancer regimen (n=18, October 2026).",
  "fielded_at": "2026-10-09",
  "published_at": "2026-10-09",
  "modified_at": "2026-11-12",
  "audience": {
    "title": "US oncologists",
    "country": "US",
    "n": 18
  },
  "engine": "ask_brox",
  "author": "Lilith, Brox research agent",
  "reviewer": "Lilith, AI reviewed",
  "findings": [
    {
      "anchor": "f1",
      "claim": "14 of 18 US oncologists say prior authorization or coverage denials most often delay their first prescription of a newly approved first-line regimen; none named unfamiliar side effects or a formulary review.",
      "value": 14,
      "unit": "count",
      "base": 18,
      "segment": null
    },
    {
      "anchor": "f2",
      "claim": "Shown a new regimen with a clear survival benefit that is not yet in the NCCN guidelines, 7 of 18 would prescribe it now and 10 would wait, 5 for the listing and 5 for confirmed payer coverage.",
      "value": 7,
      "unit": "count",
      "base": 18,
      "segment": null
    },
    {
      "anchor": "f3",
      "claim": "Asked what a manufacturer could show them to shorten the wait, 10 of 18 chose mature overall survival data and 7 chose confirmed coverage with a patient access program; none chose real-world community data or a side-effect guide.",
      "value": 10,
      "unit": "count",
      "base": 18,
      "segment": null
    },
    {
      "anchor": "f4",
      "claim": "The base is small and mixed: 14 medical, 2 radiation and 2 surgical oncologists. The headline holds among the medical oncologists alone, 11 of 14.",
      "value": 11,
      "unit": "count",
      "base": 14,
      "segment": "Medical oncologists"
    }
  ],
  "tabulation": [
    {
      "question": "When the FDA approves a new first-line regimen in a cancer you treat, how soon after approval do you usually first prescribe it to a suitable patient?",
      "option": "Within a month",
      "count": 3,
      "pct": 16.7,
      "base": 18
    },
    {
      "question": "When the FDA approves a new first-line regimen in a cancer you treat, how soon after approval do you usually first prescribe it to a suitable patient?",
      "option": "One to three months",
      "count": 8,
      "pct": 44.4,
      "base": 18
    },
    {
      "question": "When the FDA approves a new first-line regimen in a cancer you treat, how soon after approval do you usually first prescribe it to a suitable patient?",
      "option": "Three to six months",
      "count": 6,
      "pct": 33.3,
      "base": 18
    },
    {
      "question": "When the FDA approves a new first-line regimen in a cancer you treat, how soon after approval do you usually first prescribe it to a suitable patient?",
      "option": "Six to twelve months",
      "count": 1,
      "pct": 5.6,
      "base": 18
    },
    {
      "question": "When the FDA approves a new first-line regimen in a cancer you treat, how soon after approval do you usually first prescribe it to a suitable patient?",
      "option": "More than a year",
      "count": 0,
      "pct": 0,
      "base": 18
    },
    {
      "question": "Which single thing most often triggers your first prescription of a newly approved first-line regimen?",
      "option": "The pivotal trial data alone",
      "count": 6,
      "pct": 33.3,
      "base": 18
    },
    {
      "question": "Which single thing most often triggers your first prescription of a newly approved first-line regimen?",
      "option": "Its listing in the NCCN guidelines",
      "count": 9,
      "pct": 50,
      "base": 18
    },
    {
      "question": "Which single thing most often triggers your first prescription of a newly approved first-line regimen?",
      "option": "Payer coverage being in place",
      "count": 0,
      "pct": 0,
      "base": 18
    },
    {
      "question": "Which single thing most often triggers your first prescription of a newly approved first-line regimen?",
      "option": "Seeing respected peers use it",
      "count": 1,
      "pct": 5.6,
      "base": 18
    },
    {
      "question": "Which single thing most often triggers your first prescription of a newly approved first-line regimen?",
      "option": "A tumor board recommendation",
      "count": 2,
      "pct": 11.1,
      "base": 18
    },
    {
      "question": "A newly approved first-line regimen shows a clear overall survival benefit but is not yet listed in the NCCN guidelines. What would you do for a suitable patient today?",
      "option": "Prescribe it now",
      "count": 7,
      "pct": 38.9,
      "base": 18
    },
    {
      "question": "A newly approved first-line regimen shows a clear overall survival benefit but is not yet listed in the NCCN guidelines. What would you do for a suitable patient today?",
      "option": "Prescribe it only for selected patients",
      "count": 1,
      "pct": 5.6,
      "base": 18
    },
    {
      "question": "A newly approved first-line regimen shows a clear overall survival benefit but is not yet listed in the NCCN guidelines. What would you do for a suitable patient today?",
      "option": "Wait for the NCCN listing",
      "count": 5,
      "pct": 27.8,
      "base": 18
    },
    {
      "question": "A newly approved first-line regimen shows a clear overall survival benefit but is not yet listed in the NCCN guidelines. What would you do for a suitable patient today?",
      "option": "Wait until payer coverage is confirmed",
      "count": 5,
      "pct": 27.8,
      "base": 18
    },
    {
      "question": "What most often delays your first prescription of a newly approved first-line regimen?",
      "option": "Waiting for the guideline listing",
      "count": 3,
      "pct": 16.7,
      "base": 18
    },
    {
      "question": "What most often delays your first prescription of a newly approved first-line regimen?",
      "option": "Prior authorization or coverage denials",
      "count": 14,
      "pct": 77.8,
      "base": 18
    },
    {
      "question": "What most often delays your first prescription of a newly approved first-line regimen?",
      "option": "The patient's out-of-pocket cost",
      "count": 1,
      "pct": 5.6,
      "base": 18
    },
    {
      "question": "What most often delays your first prescription of a newly approved first-line regimen?",
      "option": "Little experience managing its side effects",
      "count": 0,
      "pct": 0,
      "base": 18
    },
    {
      "question": "What most often delays your first prescription of a newly approved first-line regimen?",
      "option": "Institutional pathway or formulary approval",
      "count": 0,
      "pct": 0,
      "base": 18
    },
    {
      "question": "Which of these could a manufacturer show you that would most shorten the time before you first prescribe a new first-line regimen?",
      "option": "Mature overall survival data",
      "count": 10,
      "pct": 55.6,
      "base": 18
    },
    {
      "question": "Which of these could a manufacturer show you that would most shorten the time before you first prescribe a new first-line regimen?",
      "option": "Real-world outcomes from community practice",
      "count": 0,
      "pct": 0,
      "base": 18
    },
    {
      "question": "Which of these could a manufacturer show you that would most shorten the time before you first prescribe a new first-line regimen?",
      "option": "A side-effect management guide with nurse support",
      "count": 0,
      "pct": 0,
      "base": 18
    },
    {
      "question": "Which of these could a manufacturer show you that would most shorten the time before you first prescribe a new first-line regimen?",
      "option": "Confirmed payer coverage and a patient access program",
      "count": 7,
      "pct": 38.9,
      "base": 18
    },
    {
      "question": "Which of these could a manufacturer show you that would most shorten the time before you first prescribe a new first-line regimen?",
      "option": "Data in patients like mine, such as older or comorbid patients",
      "count": 1,
      "pct": 5.6,
      "base": 18
    }
  ],
  "what_this_is": "Predicted responses from Brox clones, each built from a long-form interview with a real person. Tabulation only: question, option, count, percentage, base. Never per-clone rows.",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "downloads": {
    "csv": "https://reports.brox.ai/insights/oncologists-say-prior-authorization-not-guidelines-delays-new-first-line-cancer-regimens.csv",
    "json": "https://reports.brox.ai/insights/oncologists-say-prior-authorization-not-guidelines-delays-new-first-line-cancer-regimens.json",
    "markdown": "https://reports.brox.ai/insights/oncologists-say-prior-authorization-not-guidelines-delays-new-first-line-cancer-regimens.md",
    "html": "https://reports.brox.ai/insights/oncologists-say-prior-authorization-not-guidelines-delays-new-first-line-cancer-regimens"
  }
}
